期刊
INTERNATIONAL JOURNAL OF PHARMACEUTICS
卷 454, 期 2, 页码 775-783出版社
ELSEVIER
DOI: 10.1016/j.ijpharm.2013.05.017
关键词
Nanostructured lipid carriers; Macrophages; Colonic delivery; Inflammatory bowel disease; Budesonide
资金
- University of the Basque Country UPV/EHU
- Basque Government's Department of Education, Universities and Investigation [IT-341-10]
- Fonds pour la Formation a la Recherche dans l'Industrie et dans l'Agriculture (F.R.I.A.)
The challenge for the treatment of inflammatory bowel disease (IBD) is the delivery of the drug to the site of inflammation. Because nanoparticles have the ability to accumulate in inflamed regions, the aim of the present study was to evaluate nanostructured lipid carriers (NLCs) as nanoparticulate drug delivery systems for the treatment of IBD. Budesonide (BDS) was chosen as a candidate anti-inflammatory drug. BDS-loaded NLCs (BDS-NLC) produced by high-pressure homogenization had a size of 200 nm and a negative zeta potential. BDS-NLCs reduced the TNF-alpha secretion by activated macrophages (J774 cells). BDS-NLCs were more active in a murine model of dextran sulfate-induced colitis when compared with Blank-NLCs or a BDS suspension: BDS-NLCs decreased neutrophil infiltration, decreased the levels of the pro-inflammatory cytokines IL-1 beta and TNF-alpha in the colon and improved the histological scores of the colons. These data suggest that NLCs could be a promising alternative to polymeric nanoparticles as a targeted drug delivery system for IBD treatment. (C) 2013 Elsevier B. V. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据